NCT04280588

Fingolimod in COVID-19

Withdrawn Phase 2 Last updated 13 November 2020

What this trial tests

Phase 2 trial testing Fingolimod 0.5 mg in Coronavirus Disease (COVID-19). Withdrawn.

Timeline

22 February 2020

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	First Affiliated Hospital of Fujian Medical University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	22 February 2020
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

• Fingolimod 0.5 mg — full drug profile →

Conditions studied

• Coronavirus Disease (COVID-19) — all drugs for Coronavirus Disease (COVID-19) →

Sponsor

First Affiliated Hospital of Fujian Medical University

Who can join

Adults 18 to 80, any sex, with Coronavirus Disease (COVID-19). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although immune-inflammatory treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, according to the pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of immune modulator together with ventilator support should be considered for the severe patients to prevent ARDS development. The sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology modulator which has been widely used in multiple sclerosis.The aim of this study was to determine whether the efficacy of fingolimod for a novel coronavirus disease (COVID-19).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The trinity of COVID-19: immunity, inflammation and intervention.
   Tay MZ, Poh CM, Rénia L, MacAry PA, et al · · 2020 · cited 2973× · PMID 32346093 · DOI 10.1038/s41577-020-0311-8
2. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
   Driggin E, Madhavan MV, Bikdeli B, Chuich T, et al · · 2020 · cited 1272× · PMID 32201335 · DOI 10.1016/j.jacc.2020.03.031
3. COVID-19: Transmission, prevention, and potential therapeutic opportunities.
   Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
4. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
   Catanzaro M, Fagiani F, Racchi M, Corsini E, et al · · 2020 · cited 425× · PMID 32467561 · DOI 10.1038/s41392-020-0191-1
5. A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
   Tu YF, Chien CS, Yarmishyn AA, Lin YY, et al · · 2020 · cited 411× · PMID 32290293 · DOI 10.3390/ijms21072657
6. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
   Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
7. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
   Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
8. Clinical trials on drug repositioning for COVID-19 treatment.
   Rosa SGV, Santos WC. · · 2020 · cited 225× · PMID 32256547 · DOI 10.26633/rpsp.2020.40